Pan-tumour antigen therapy candidate enters the clinic
The first US participant has been dosed in Moderna’s Phase I study evaluating mRNA-4106, a novel pan-tumour antigen therapy candidate, in patients with advanced or metastatic solid tumours.
The first dose was administered at START Center for Cancer Research (START) in San Antonio by Dr Amita Patnaik.
Dr Patnaik said: “mRNA represents a bold new frontier in cancer immunotherapy, and we’re proud to provide our patients access to this innovative treatment as part of a first-in-human trial. At START, our mission is to ensure that scientific breakthroughs translate into real-world options for patients—this study is a powerful example of that commitment.”
The Phase I trial will evaluate the safety, pharmacodynamics, immunogenicity and preliminary efficacy of mRNA-4106 administered alone and in combination with checkpoint inhibitor therapy.
mRNA-4106’s multivalent approach aims to broaden treatment options for patients with cancer, advancing the field beyond single-targeted immunotherapies.
“This milestone reflects the core of who we are at START—accelerating the next generation of cancer therapies by bringing them directly to patients in the communities where they live,” said Nick Slack, Chairman and CEO of START. “We’re proud to support Moderna in advancing this innovation into the clinic, reinforcing our commitment to faster, more accessible early phase trials that expand opportunity and impact for patients and sponsors alike.”
“With mRNA-4106, we sought to design an inclusive therapy that encodes for antigens commonly shared across patients and tumour types. We are thrilled to be able to bring this medicine to trial participants, and in partnership with forward-thinking site networks like START, further showcase the promise of mRNA to transform cancer care,” added Dr Rose Loughlin, Executive Vice President of Research at Moderna.
Diana Spencer, Senior Digital Content Editor, DDW
